CJC-1295: 28 Answers for Your Next Doctor Visit
These Answers Separate Measured Changes From Unproved Claims
CJC-1295 is an experimental peptide studied for raising growth-related hormones. These answers explain common claims and how little testing can say about your care.
The numbered links lead to the studies behind the figures. I'd bring your own questions to the doctor, since these answers can't choose treatment.
CJC-1295 Hormone Rises Don’t Establish Health Gains
Teichman's 2006 study measured hormone levels, leaving health benefits unproved. Growth hormone rose 2–10-fold for at least 6 days with CJC-1295 and DAC, its added part [1].
Lab estimates suggest a shorter response of about 30–60 minutes without DAC. A liver hormone also rose [1]; higher growth hormone may cause your kidneys to retain salt, with water staying too [8].
CJC-1295 Testing Found Brief Skin Reactions and Dizziness
The trial by Teichman in 2006 was short, leaving lasting safety uncertain. About 23% had redness at the shot site, and about 22% had brief flushing or dizziness; headaches also occurred [13].
Reports describe swelling from extra salt and water [8]. The FDA's 2024 concerns included unwanted material triggering your immune system, the body's defenses [16].
CJC-1295 Studies Didn’t Measure Testosterone Levels
Testosterone, a sex hormone, wasn't measured in the CJC-1295 trials. Teichman 2006 and Ionescu 2006 examined growth-related hormones instead [19].
CJC-1295 acts on growth hormone cells, without directly acting on cells that control sex hormones. A suggested indirect effect hasn't been confirmed, so a testosterone rise isn't proved for you.
CJC-1295 Testing Used Different Spacing for Different Forms
Teichman 2006 studied CJC-1295 with DAC using shots spaced a week or two apart [1]. The added DAC part keeps that form in blood longer.
Mod GRF 1-29 names the form without the added part. More frequent shots reflect that form's expected brief action, rather than a schedule established for your treatment.
CJC-1295 Studies Don’t Predict When You’d Notice a Change
No human trial has established when you'd feel a change from CJC-1295. Teichman's 2006 trial found higher blood-test hormone levels within 2–6 hours [1].
Rats and mice had muscle and fat changes over 4–8 weeks. Those animals' changes can't tell you whether or when your daily tasks would feel easier.
CJC-1295 Ipamorelin Side Effects Still Need a Comparison
Ipamorelin is a separate compound that also prompts growth hormone release. The pair hasn't had a full human safety trial; concerns about swelling, flushing, and shot reactions come from CJC-1295 alone [13].
A larger hormone rise might make your kidneys keep more water [8]. A trial hasn't measured how often those problems occur with both compounds.
CJC-1295 Ipamorelin Claims About Bones Rely on Other Testing
Small reports haven't established health benefits from CJC-1295 with ipamorelin. Muscle and bone claims draw on animal work [10] [11], leaving results for you unproved.
Tesamorelin, a different compound that prompts growth hormone release, reduced deep belly fat in human trials [9]. Those people didn't receive this pair, so you can't transfer the benefit.
CJC-1295 with DAC Has an Attachment the Shorter Form Lacks
An added part called DAC attaches CJC-1295 to a protein in blood and slows removal. Without DAC, lab work estimates about 30 minutes for half to leave blood [3][14].
That shorter timing hasn't been measured in published human testing. The DAC form keeps levels higher between bursts, which explains the different study schedules without choosing one for you.
Modified GRF 1-29 Is Another Name for Shorter-Lasting CJC-1295
Mod GRF 1-29 and 'Modified GRF 1-29' name CJC-1295 without DAC. Four amino acids, the parts joined together to form proteins, were changed to slow breakdown.
There's no added attachment to a blood protein in this form. 'Mod GRF 1-29' and 'CJC-1295 no DAC' mean the same compound [14], so you aren't comparing separate treatments.
CJC-1295 Forms Lack Proof That One Helps You More
No human study has compared the two forms for better health results [14]. The form with DAC keeps hormone levels raised longer; the other form is expected to cause brief bursts.
You can ask which form a health claim actually concerns. Different hormone timing doesn't tell you which form would help your reason for seeking care.
CJC-1295 and Ipamorelin Don’t Have a Tested Timing Plan
Human trials haven't established timing for giving CJC-1295 with ipamorelin. Reports describe shots, while volunteer testing found half the ipamorelin left blood in about 2 hours [6].
The longer-lasting form remains active between brief responses. Meals can affect hormone measurements [1][3], but those study findings don't set a plan for your care.
CJC-1295 Pairing Expectations Come From Different Compounds
CJC-1295 and ipamorelin prompt growth hormone release through separate processes. Researchers expect a larger rise together, but the pair lacks a dedicated human trial.
Norman's 2013 study combined GHRP-2, another growth hormone releasing compound, with the body's hormone that prompts growth hormone release [7]. In animal testing, ipamorelin alone didn't clearly raise cortisol, the stress hormone, or the hormone prompting cortisol [5]; that's not proof of paired benefit for you.
CJC-1295 Names Can Sound Like More Than One Choice
'CJC-1295 no DAC' and 'Modified GRF 1-29' describe the same compound [14]. Mod GRF 1-29 is another name for that shorter-lasting form.
Different names on listings don't mean you're looking at different compounds. You can ask whether a claim concerns this form or the longer-lasting form with an added part.
CJC-1295 Time in Blood Was Measured Only for the DAC Form
Jetté 2005 lab work supports about 30 minutes for half the shorter-lasting CJC-1295 to leave blood [3]. Teichman 2006 measured several days for half the longer-lasting CJC-1295 form to leave [1].
DAC attaches that form to a blood protein, explaining the roughly 250-fold difference. You can't use either timing to predict how much better you'd feel.
CJC-1295 Swelling Can Ease, Though Your Response Is Unknown
Compounds that raise growth hormone often bring reports of swelling. Your kidneys may retain more salt, which also keeps water in the body [8].
Larger amounts tend to cause more swelling in the findings described. Swelling usually eased after use stopped in animals, which doesn't tell you how quickly yours would ease.
CJC-1295’s FDA Review Didn’t Make the Compound Approved
As of 2026, the FDA hasn't approved CJC-1295 for any use. Its December 2024 pharmacy review raised concerns that unwanted material could trigger an immune system reaction [16].
Reviewing pharmacy use isn't the same as approving a medicine. You can ask how your doctor would explain those concerns for any proposed care.
CJC-1295 Is a Peptide With a Different Action From Steroids
CJC-1295 is a peptide, a short chain of parts that make proteins. Steroids have a different structure and action; the peptide prompts the gland beneath your brain to release growth hormone [12].
The compound doesn't act through the same cells as steroids. That difference can't establish safety or a benefit for your health.
CJC-1295’s Longer Stay Doesn’t Establish an Advantage Over Sermorelin
Sermorelin is a separate compound that prompts growth hormone release. Sermorelin takes about 10–12 minutes for half to leave blood; four changed protein parts help CJC-1295 resist breakdown [15].
The lab estimate without DAC is about 30 minutes, while DAC extends the stay to days. Sermorelin has a past FDA approval that CJC-1295 lacks; longer action doesn't prove better results for you.
Short CJC-1295 Follow-Up Can’t Settle Later Hormone Changes
Human safety testing hasn't established CJC-1295 risks beyond 3 months. Ionescu and Frohman 2006 found usual hormone bursts continuing during testing [2].
Published CJC-1295 trials didn't report reduced growth hormone after testing ended [18]. You can't use that short follow-up to predict hormone production after much longer use.
CJC-1295 Breaks Haven’t Been Tested Against Use Without Breaks
No human study has compared 5 days with shots and 2 days off against ongoing use. A benefit from breaks hasn't been established.
Teichman's 2006 trial lasted up to 49 days without breaks [1]. Mice received shots over five weeks without breaks [4], leaving the question unanswered for your care.
CJC-1295 Longer-Use Accounts Don’t Show How Long Use Is Safe
Descriptions of four to twelve weeks don't establish a safe length of treatment. Teichman's 2006 study found growth-related hormones stayed raised over fourteen days after one shot [1].
Accounts of longer use mainly come from pharmacies describing care rather than published trials. Those accounts can't tell you whether prolonged use would be safe.
CJC-1295 Storage Advice Wasn’t Tested Directly on This Compound
The storage estimates come from similar compounds, leaving CJC-1295 itself untested. The advice describes refrigeration at 2–8°C, just above freezing, for about 30 days after mixing.
Freezing and thawing can damage the compound. Those general estimates can't establish that a particular vial mixed for your care remains safe.
CJC-1295 Ipamorelin Muscle Benefits Aren’t Established in People
Related compounds preserved muscle and reduced fat in animal studies [11]. Those findings don't establish what CJC-1295 with ipamorelin would do for your muscles.
Human testing found less deep belly fat with tesamorelin, a different compound [9]. The pair's few human reports lack a comparison with people who didn't receive the pair.
MK-677 and CJC-1295 Ipamorelin Lack a Direct Human Test
No trial has directly compared MK-677 with CJC-1295 ipamorelin in people [20]. The swallowed compound, also called ibutamoren, raises growth hormone over a 24-hour period.
The paired peptides are given by shot and are expected to prompt hormone bursts. Differences in timing and reported problems don't show which would help you more.
CJC-1295 Digestion Leaves Pill Claims Without Proof
Published studies haven't shown that swallowed CJC-1295 reaches blood and works [17]. Its weight is about 3,647 daltons, tiny units used for protein parts too small for your kitchen scale.
Digestion breaks compounds of this size apart before they reach blood. The human and animal testing used shots beneath the skin.
CJC-1295 Meal Timing Helps Researchers Compare Blood Tests
Insulin, the hormone controlling blood sugar, and higher sugar levels can weaken growth hormone release. Testing before meals limits that change during CJC-1295 measurements.
Jetté 2005 and Teichman 2006 describe that reason for studying the compound before eating [1][3]. Those choices concern the study comparison, without setting medicine timing for you.
CJC-1295 Sleep Claims Lack a Comparison With Untreated People
Research users of the form without DAC describe vivid dreams and brief trouble sleeping. Those experiences and small patient reports weren't compared with an untreated group; a trial hasn't checked the claimed effects.
Some accounts mention shots near bedtime, when growth hormone normally rises. That explanation is untested, so you don't have proof of better sleep.
CJC-1295 Partners Differ in Their Effects on the Stress Hormone
GHRP-2, a compound that prompts growth hormone release, can cause larger bursts and raise cortisol, a hormone that helps the body handle stress. The hormone that tells the body to make cortisol rose as well.
In animals, researchers found the ipamorelin amount giving half the largest growth hormone rise [5]. Even at 200 times that amount, cortisol and its prompting hormone didn't rise; that doesn't prove paired benefits.
CJC-1295 Has No Proven Health Advantage Over Growth Hormone Shots
No direct human trial shows better benefits from CJC-1295 than growth hormone shots [18]. The compound prompts the gland's own production, while hormone shots supply hormone and can reduce that production.
Growth hormone has approved uses, whereas CJC-1295 hasn't received approval. Those differences don't establish the right treatment for your concern.
CJC-1295 Indirect Effects on Testosterone Are Only Suggested
Trials haven't confirmed that CJC-1295 directly raises testosterone [19]. Growth hormone cells respond to the compound, while cells controlling sex hormones don't respond directly.
Researchers suggest other growth-related hormones might indirectly affect cells that make testosterone. That idea hasn't given you measured testosterone results to rely on.